396 related articles for article (PubMed ID: 29684967)
21. Adalimumab in ulcerative colitis: hypes and hopes.
Fiorino G; Peyrin-Biroulet L; Repici A; Malesci A; Danese S
Expert Opin Biol Ther; 2011 Jan; 11(1):109-16. PubMed ID: 21133817
[TBL] [Abstract][Full Text] [Related]
22. Golimumab for moderately to severely active ulcerative colitis.
Kedia S; Ahuja V; Makharia GK
Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
[TBL] [Abstract][Full Text] [Related]
23. Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort.
Bálint A; Rutka M; Kolar M; Bortlik M; Duricova D; Hruba V; Lukas M; Mitrova K; Malickova K; Lukas M; Szepes Z; Nagy F; Palatka K; Lovas S; Végh Z; Kürti Z; Csontos Á; Miheller P; Nyári T; Bor R; Milassin Á; Fábián A; Szántó K; Lakatos PL; Molnár T; Farkas K
Expert Opin Biol Ther; 2018 Nov; 18(11):1181-1187. PubMed ID: 30277084
[TBL] [Abstract][Full Text] [Related]
24. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.
Farkas K; Rutka M; Ferenci T; Nagy F; Bálint A; Bor R; Milassin Á; Fábián A; Szántó K; Végh Z; Kürti Z; Lakatos PL; Szepes Z; Molnár T
Expert Opin Biol Ther; 2017 Nov; 17(11):1325-1332. PubMed ID: 28819991
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center.
Farkas K; Rutka M; Bálint A; Nagy F; Bor R; Milassin Á; Szepes Z; Molnár T
Expert Opin Biol Ther; 2015; 15(9):1257-62. PubMed ID: 26134250
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
Hernandez L; Kuwabara H; Shah A; Yamabe K; Burnett H; Fahrbach K; Koufopoulou M; Iwakiri R
Pharmacoeconomics; 2020 Jan; 38(1):69-84. PubMed ID: 31552601
[TBL] [Abstract][Full Text] [Related]
27. Safety Profile of Biologic Drugs in the Therapy of Ulcerative Colitis: A Systematic Review and Network Meta-Analysis.
Moćko P; Kawalec P; Pilc A
Pharmacotherapy; 2016 Aug; 36(8):870-9. PubMed ID: 27312826
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis.
Vande Casteele N; Khanna R
Pharm Res; 2017 Aug; 34(8):1556-1563. PubMed ID: 28374338
[TBL] [Abstract][Full Text] [Related]
29. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
Jahnsen J; Detlie TE; Vatn S; Ricanek P
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
[TBL] [Abstract][Full Text] [Related]
30. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease.
Doherty G; Katsanos KH; Burisch J; Allez M; Papamichael K; Stallmach A; Mao R; Berset IP; Gisbert JP; Sebastian S; Kierkus J; Lopetuso L; Szymanska E; Louis E
J Crohns Colitis; 2018 Jan; 12(1):17-31. PubMed ID: 28981623
[TBL] [Abstract][Full Text] [Related]
31. Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date.
Thukral C; Cheifetz A; Peppercorn MA
Drugs; 2006; 66(16):2059-65. PubMed ID: 17112300
[TBL] [Abstract][Full Text] [Related]
32. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
33. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.
Komaki Y; Yamada A; Komaki F; Micic D; Ido A; Sakuraba A
Aliment Pharmacol Ther; 2017 Apr; 45(8):1043-1057. PubMed ID: 28239873
[TBL] [Abstract][Full Text] [Related]
34. Golimumab for the treatment of ulcerative colitis.
Flamant M; Paul S; Roblin X
Expert Opin Biol Ther; 2017 Jul; 17(7):879-886. PubMed ID: 28472597
[TBL] [Abstract][Full Text] [Related]
35. Frequency and prognostic role of mucosal healing in patients with Crohn's disease and ulcerative colitis after one-year of biological therapy.
Farkas K; Lakatos PL; Szűcs M; Pallagi-Kunstár É; Bálint A; Nagy F; Szepes Z; Vass N; Kiss LS; Wittmann T; Molnár T
World J Gastroenterol; 2014 Mar; 20(11):2995-3001. PubMed ID: 24659890
[TBL] [Abstract][Full Text] [Related]
36. Comparative effectiveness of antitumour necrosis factor agents and vedolizumab in ulcerative colitis.
Davis R; McParland P; Dodd S; Storey D; Probert C; Collins P; Skouras T; Steel A; Derbyshire E; Dibb M; Subramanian S
Eur J Gastroenterol Hepatol; 2019 Jun; 31(6):661-667. PubMed ID: 30855421
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom.
Wilson MR; Bergman A; Chevrou-Severac H; Selby R; Smyth M; Kerrigan MC
Eur J Health Econ; 2018 Mar; 19(2):229-240. PubMed ID: 28271250
[TBL] [Abstract][Full Text] [Related]
38. Up-to-date surgery for ulcerative colitis in the era of biologics.
Yamamoto T; Carvello M; Lightner AL; Spinelli A; Kotze PG
Expert Opin Biol Ther; 2020 Apr; 20(4):391-398. PubMed ID: 31948294
[No Abstract] [Full Text] [Related]
39. Infliximab Can Be Effective in Pediatric Patients with Ulcerative Colitis and Primary Failure of Adalimumab.
Farr R; Karam L; Kitagawa S; Kellermayer R
Ann Clin Lab Sci; 2022 Sep; 52(5):796-801. PubMed ID: 36261187
[TBL] [Abstract][Full Text] [Related]
40. Current therapeutic recommendations: infliximab for ulcerative colitis.
Shen EH; Das KM
J Clin Gastroenterol; 2004 Oct; 38(9):741-5. PubMed ID: 15365397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]